A Multicenter, Open-Label, Randomized, Phase Ib/II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of IN10018 Combined With Taxane and Anti-PD-1/L1 Monoclonal Antibody in Previously-treated Solid Tumors
Latest Information Update: 08 May 2025
At a glance
- Drugs Ifebemtinib (Primary) ; Paclitaxel (Primary) ; Tislelizumab (Primary)
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors InxMed
Most Recent Events
- 30 Apr 2025 Planned End Date changed from 1 Jul 2026 to 31 Dec 2026.
- 30 Apr 2025 Planned primary completion date changed from 1 Dec 2025 to 31 Dec 2026.
- 30 Apr 2025 Planned initiation date changed from 1 Aug 2023 to 13 Aug 2025.